Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.
Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S; International HypoCCS Advisory Board.
Hartman ML, et al.
J Clin Endocrinol Metab. 2013 Mar;98(3):980-8. doi: 10.1210/jc.2012-2684. Epub 2013 Jan 23.
J Clin Endocrinol Metab. 2013.
PMID: 23345098
Free PMC article.
CONCLUSIONS: In GH-deficient adults, there was no evidence for a GH treatment effect on death, cancer, intracranial tumor recurrence, diabetes, or cardiovascular events, although the follow-up period was of insufficient duration to be conclusive for these long-term events. …
CONCLUSIONS: In GH-deficient adults, there was no evidence for a GH treatment effect on death, cancer, intracranial tumor recurrence, diabet …